<DOC>
	<DOCNO>NCT02823184</DOCNO>
	<brief_summary>The aim study evaluate endoplasmic reticulum stress marker predictive response hydroxyurea polycythemia vera ( PV ) essential thrombocythemia ( ET ) .</brief_summary>
	<brief_title>Endoplasmic Reticulum Stress Resistance Treatments Ph-negative Myeloproliferative Neoplasms</brief_title>
	<detailed_description>The recent discovery calreticulin mutation myeloproliferative neoplasms point unexpected role endoplasmic reticulum biology pathophysiology disease . Otherwise , association endoplasmic reticulum stress solid cancer , particular resistance chemotherapy , well document , contrary hematological malignancy . The study aim evaluate endoplasmic reticulum stress marker predictor response hydroxyurea polycythemia vera essential thrombocythemia patient . The main objective correlate endoplasmic reticulum stress ( define splice XBP1 30 % ) rate complete response 6 month accord 2009 ELN criterion . This observational retrospective study .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Polycythemia</mesh_term>
	<mesh_term>Polycythemia Vera</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Thrombocytosis</mesh_term>
	<mesh_term>Thrombocythemia , Essential</mesh_term>
	<criteria>ET PV patient diagnose acceleration phase treat hydroxyurea follow period least 6 month follow treatment start . Diagnosis criterion PV : WHO criteria PV : Acquired JAK2V617F mutation &gt; 5 % Absence evident cause secondary polycythemia Diagnosis criterion ET : Platelet count &gt; 450 G/L Absence PV Chronic Myeloid Leukemia Bone marrow biopsy prefer necessary absence reactional cause ( CRP ferritin level normal ) and/or presence acquire JAK2V617F , CALR exon 9 MPL exon 10 Availability RNA sample total leukocyte start treatment . In absence clonality marker , presence secondary cause : Thrombocytosis : Inflammatory syndrom ( CRP SV increase ) Iron deficiency ( decreased ferritin level increase soluble transferrin receptor level ) Polycythemia : Increased normal level EPO context : Hypoxia , respiratory insufficiency Sleep apnea syndrome Hyperaffin hemoglobin Absence treatment hydroxyurea Treatment anagrelide , P32 , pipobroman , interferon without subsequent hydroxyurea treatment . Concommitant treatment cancer chemotherapy ( context solid cancer example ) . Diagnostic transformation acute leukemia Treatment hydroxyurea le 6 month Bad observance cytotoxic treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Myeloproliferative neoplasm</keyword>
	<keyword>Endoplasmic reticulum stress</keyword>
</DOC>